-
公开(公告)号：EP3416984A1
公开(公告)日：2018-12-26
申请号：EP17706644.6
申请日：2017-02-10
Applicant: Elanco US Inc.
Inventor： PANCOOK, James David
CPC classification number: C07K16/2809 , A61K2039/505 , C07K16/2887 , C07K2317/24 , C07K2317/31 , C07K2317/33
Abstract: The disclosure relates to caninized chimeric anti-CD20 antibodies to the canine protein CD20 and methods of use to treat certain disorders such as non-Hodgkins B-cell lymphoma in dogs.
-
公开(公告)号：EP3411410A1
公开(公告)日：2018-12-12
申请号：EP17746860.0
申请日：2017-01-23
Applicant: Innovent Biologics (Suzhou) Co., Ltd.
Inventor： BARUAH, Hemanta , CHEN, Cheng , LIU, Xiaolin , TSUN, Andy , YU, De-Chao Michael
IPC: C07K16/28 , C12N5/10 , A61K39/395 , A61P35/00
CPC classification number: C07K16/2818 , A61K2039/505 , C07K2317/33 , C07K2317/76 , C07K2317/92 , C12N5/10
Abstract: The present invention provides antibodies that bind human programmed cell death 1 (PD-1). These antibodies may be useful for treating cancer alone and in combination with chemotherapy and other cancer therapeutics.
-
公开(公告)号：EP3411403A1
公开(公告)日：2018-12-12
申请号：EP17703379.2
申请日：2017-02-02
Applicant: Amgen Research (Munich) GmbH
Inventor： RAUM, Tobias , MUENZ, Markus , BROZY, Johannes , KUFER, Peter , HOFFMANN, Patrick , FRIEDRICH, Matthias , RATTEL, Benno , BOGNER, Pamela , WOLF, Andreas , POMPE, Cornelius
CPC classification number: C07K16/30 , C07K16/28 , C07K16/2803 , C07K16/2809 , C07K16/2863 , C07K16/2875 , C07K16/2887 , C07K16/3053 , C07K16/468 , C07K2317/31 , C07K2317/33 , C07K2317/52 , C07K2317/524 , C07K2317/526 , C07K2317/53 , C07K2317/64 , C07K2317/94 , C07K2319/00
Abstract: The present invention provides bispecific antibody constructs of a specific Fc modality characterized by comprising a first domain binding to a target cell surface antigen, a second domain binding to an extracellular epitope of the human and/or the Macaca CD3ε chain and a third domain, which is the specific Fc modality. Moreover, the invention provides a polynucleotide, encoding the antibody construct, a vector comprising this polynucleotide, host cells, expressing the construct and a pharmaceutical composition comprising the same.
-
公开(公告)号：EP3411071A1
公开(公告)日：2018-12-12
申请号：EP17849891.1
申请日：2017-10-20
Applicant: I-MAB
Inventor： WANG, Zhengyi , FANG, Lei , GUO, Bingshi , ZANG, Jingwu
IPC: A61K39/395 , A61P35/00 , C07K14/705 , C07K16/00 , C07K16/18 , C07K16/28
CPC classification number: A61P35/00 , A61K2039/505 , A61K2039/804 , A61P35/02 , C07K14/705 , C07K16/2803 , C07K19/00 , C07K2317/33 , C07K2317/34 , C07K2317/73 , C07K2317/76 , C07K2317/94
Abstract: The present invention provides novel CD47 antibodies or immunologically active fragments thereof that have low immunogenicity in humans and cause low or no level of red blood cell depletion or hemagglutination, as well as pharmaceutical compositions containing such antibodies that can be used for treatment diseases mediated by CD47 or inhibition of phagocytosis or platelet aggregation.
-
公开(公告)号：EP3408299A1
公开(公告)日：2018-12-05
申请号：EP17702059.1
申请日：2017-01-25
Applicant: INSERM - Institut National de la Santé et de la Recherche Médicale , Universite Paris-Sud
Inventor： LENTING, Petrus , AYME, Gabriel , DENIS, Cécile , CHRISTOPHE, Olivier
IPC: C07K16/36 , C07K14/755 , C07K14/745 , A61P7/04
CPC classification number: C07K16/36 , A61K2039/505 , C07K14/745 , C07K14/755 , C07K2317/33 , C07K2317/569 , C07K2317/92 , C07K2317/94 , C07K2319/31
Abstract: The invention relates to isolated single-domain antibodies (sdAb) directed against von Willebrand Factor (VWF) D'D3 domain and chimeric polypeptides comprising thereof such as blood clotting factors and their uses in therapy such as in the prevention and treatment of hemostatic disorders. The invention also relates to a method of extending or increasing half-life of a therapeutic polypeptide comprising a step of adding to the polypeptide sequence of said therapeutic polypeptide at least one sdAb directed against VWF D'D3 domain.
-
Patent Agency Ranking
公开(公告)号：EP3405496A1
公开(公告)日：2018-11-28
申请号：EP17703552.4
申请日：2017-01-20
Applicant: The Scripps Research Institute , NBE-Therapeutics AG
Inventor： RADER, Christoph , PENG, Haiyong , BEERLI, Roger , WALDMEIER, Lorenz , GRAWUNDER, Ulf
IPC: C07K16/28 , C07K14/725 , A61K39/395 , A61P35/00
CPC classification number: C07K16/2803 , A61K47/6809 , A61K47/6849 , A61K47/6889 , A61K47/6903 , A61K2039/505 , A61P35/00 , A61P35/02 , C07K14/705 , C07K14/7051 , C07K2317/24 , C07K2317/33 , C07K2317/73 , C07K2317/90 , C07K2317/92 , C07K2319/00 , C07K2319/02 , C07K2319/03 , C12N9/12 , C12Y207/10001
Abstract: The invention provides antibodies, antibody drug conjugates, antibody-based fragments or antibody fragments (antigen-binding fragments), as well as antibody drug conjugates (ADCs) and chimeric antigen receptors (CARs), that specifically recognize human ROR1 and related compositions. Also provided in the invention are methods of using such antibodies in various diagnostic and therapeutic applications.
-
公开(公告)号：EP3399989A1
公开(公告)日：2018-11-14
申请号：EP16876461.1
申请日：2016-12-13
Applicant: Merck Sharp & Dohme Corp.
Inventor： MALEFYT, Rene De Waal , FAYADAT-DILMAN, Laurence , LIANG, Linda
IPC: A61K38/00 , A61K39/00 , A61K39/395 , C07K16/28 , C12P21/08
CPC classification number: C07K16/2803 , A61K38/00 , A61K39/00 , A61K2039/505 , C07K2317/24 , C07K2317/33 , C07K2317/76 , C07K2317/92 , C07K2317/94
Abstract: The present invention includes antibodies and antigen-binding fragments thereof that specifically bind to human or cynomolgous monkey LAG3 as well as immunoglobulin chains thereof and polynucleotides encoding the same along with injection devices comprising such antibodies or fragments. Vaccines including such antibodies and fragments as well as compositions comprising the antibodies and fragments (e.g., including anti-PD1 antibodies) are included in the invention. Methods for treating or preventing cancer or infection using such compositions are also provided. In addition, methods for recombinant expression of the antibodies and fragments are part of the present invention.
-
公开(公告)号：EP3394104A2
公开(公告)日：2018-10-31
申请号：EP16831950.7
申请日：2016-12-21
Applicant: Amgen Inc.
Inventor： YIE, Junming , SHI, Donghui , LLOYD, David J. , WANG, Jinghong , SIVITS, JR., Glenn N. , VENIANT-ELLISON, Murielle M. , KOMOROWSKI, Renee , AGRAWAL, Neeraj , BATES, Darren L. , CLAVETTE, Brandon C. P. , FOLTZ, Ian N. , HO, Shu-yin , MURAWSKY, Christopher , MIN, Xiaoshan , WANG, Zhulun
IPC: C07K16/28 , A61K38/26 , A61K39/395 , A61P3/10
CPC classification number: C07K16/2869 , A61K9/0019 , A61K38/1703 , A61K38/26 , A61K39/3955 , A61K2039/505 , A61K2039/54 , C07K2299/00 , C07K2317/21 , C07K2317/32 , C07K2317/33 , C07K2317/41 , C07K2317/52 , C07K2317/71 , C07K2317/76 , C07K2317/92 , A61K2300/00
Abstract: Methods of treating metabolic diseases and disorders using an antigen binding protein specific for the GIPR polypeptide are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the antigen binding protein is administered in combination with a GLP-1 receptor agonist.
-
公开(公告)号：EP3390442A1
公开(公告)日：2018-10-24
申请号：EP16875755.7
申请日：2016-12-16
Applicant: Chugai Seiyaku Kabushiki Kaisha
Inventor： SAMPEI, Zenjiro
CPC classification number: C07K16/18 , A61K2039/505 , C07K2299/00 , C07K2317/24 , C07K2317/30 , C07K2317/33 , C07K2317/55 , C07K2317/76 , C07K2317/92 , C07K2317/94 , C12N5/10
Abstract: The invention provides anti-C5 antibodies and methods of using the same. In some embodiments, an isolated anti-C5 antibody of the present invention binds to an epitope within the beta chain of C5 with a higher affinity at neutral pH than at acidic pH. The invention also provides isolated nucleic acids encoding an anti-C5 antibody of the present invention. The invention also provides host cells comprising a nucleic acid of the present invention. The invention also provides a method of producing an antibody comprising culturing a host cell of the present invention so that the antibody is produced. The invention further provides a method of producing an anti-C5 antibody comprising immunizing an animal against a polypeptide which comprises the MG1-MG2 domain of the beta chain of C5. Anti-C5 antibodies of the present invention may be for use as a medicament.
-
公开(公告)号：EP2863948B1
公开(公告)日：2018-10-24
申请号：EP13807400.0
申请日：2013-06-21
Applicant: Cytomx Therapeutics Inc.
Inventor： WEST, James, William , SAGERT, Jason, Gary , BESSETTE, Paul, H. , LOWMAN, Henry, Bernard , STAGLIANO, Nancy, E. , VASILJEVA, Olga , MENENDEZ, Elizabeth-Edna, Mary
CPC classification number: C07K16/18 , A61K39/39558 , A61K47/6803 , A61K47/6811 , A61K47/6851 , A61K49/0058 , A61K2039/505 , C07K16/28 , C07K16/2887 , C07K16/2896 , C07K2317/21 , C07K2317/33 , C07K2317/52 , C07K2317/54 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/569 , C07K2317/622 , C07K2317/73 , C07K2317/76 , C07K2317/92 , C07K2317/94 , C07K2319/00 , C07K2319/30 , C07K2319/50 , A61K2300/00
Abstract: This invention relates generally to the generation of antibodies, e.g., monoclonal antibodies including fully human monoclonal antibodies, that recognize Jagged 1 and/or Jagged 2, to antibodies, e.g., monoclonal antibodies including fully human antibodies that recognize Jagged 1 and/or Jagged 2, and nucleic acid molecules that encode antibodies, e.g., nucleic acid molecules that encode monoclonal antibodies including fully human cross-reactive antibodies that recognize both Jagged 1 and Jagged 2, and to methods of making the anti-Jagged antibodies and methods of using the anti-Jagged antibodies as therapeutics, prophylactics, and diagnostics. The invention also relates generally to activatable antibodies that include a masking moiety (MM), a cleavable moiety (CM), and an antibody (AB) that specifically bind to Jagged 1 and Jagged 2, and to methods of making and using these activatable anti-Jagged antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
-
-
-
-
-
-
-
-
-
Search Results
2058
records
(took 0.046 seconds)
